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Abstract
During advanced vasodilatory shock, arginine vasopressin (AVP) is
increasingly used to restore blood pressure and thus to reduce
catecholamine requirements. The AVP-related rise in mean arterial
pressure is due to systemic vasoconstriction, which, depending on
the infusion rate, may also reduce coronary blood flow despite an
increased coronary perfusion pressure. In a murine model of
myocardial ischaemia, Indrambarya and colleagues now report that
a 3-day infusion of AVP decreased the left ventricular ejection
fraction, ultimately resulting in increased mortality, and thus com-
pared unfavourably with a standard treatment using dobutamine.
The AVP-related impairment myocardial dysfunction did not result
from the increased left ventricular afterload but from a direct effect
on cardiac contractility. Consequently, the authors conclude that
the use of AVP should be cautioned in patients with underlying
cardiac disease.
In the previous issue of Critical Care, Indrambarya and
colleagues compared a 72-hour infusion of arginine vaso-
pressin (AVP) (infusion rate equivalent to 0.04 IU/min in a
70 kg human being), dobutamine (8.33 μg/kg/min) and
vehicle in mice that had undergone myocardial ischaemia
induced by a 1-hour ligation of the left anterior descending
coronary artery [1]. While AVP did not affect heart function in
sham control mice, echocardiography demonstrated a more
pronounced fall in the left ventricular ejection fraction at day 1
after coronary ischaemia than in the vehicle-treated and
dobutamine-treated animals, which had not resumed at day 3.
Since the heart rate, blood pressure and end-diastolic volume
remained unaffected, the decreased ejection fraction was
affiliated with a reduced stroke volume. This difference in
contractility coincided with a marked depression of the
cardiac oxytocin receptor expression and, ultimately, a nearly
doubled mortality at day 7.
How does Indrambarya and colleagues’ study compare with
the existing literature? Müller and colleagues reported recently
in this journal that AVP dose-dependently reduced coronary
blood flow in swine after transient myocardial ischaemia,
which coincided with impaired left heart diastolic relaxation
[2]. While other authors also highlighted its coronary
vasoconstrictor properties [3-6], AVP more efficiently
increased coronary blood flow in swine after closed-chest
cardiopulmonary resuscitation than adrenaline [7] and attenu-
ated the otherwise progressive rise in troponin I blood levels
during porcine faecal peritonitis-induced hypotension treated
with noradrenaline [8]. Moreover, infusing AVP was devoid of
adverse effects on the heart in patients after cardiac surgery
[9,10] and with cardiogenic shock [11,12]. Finally, supple-
menting an ongoing noradrenaline infusion in patients with
vasodilatory shock was associated with a sixfold reduction of
new-onset tachyarrhythmias when infused to supplement [13].
Direct (that is, afterload-independent) myocardial effects
unrelated to coronary vasoconstriction of AVP are also
controversially discussed: positive inotrope properties [5] and
negative inotrope properties [3,4,6] have been reported.
Obviously, any coronary hypoperfusion assumes particular
importance in this context: cardiac efficiency – that is, the
product of left ventricular pressure times the heart rate
normalized for myocardial oxygen consumption – was well
maintained under constant flow conditions [14]. Unfortu-
nately, the recent multicentre Vasopressin in Septic Shock
Trial is inconclusive on this issue: cardiac arrhythmia and
myocardial ischaemia events were identical in the two study
groups receiving vasopressin or the standard noradrenaline
treatment, but patients with cardiogenic shock, patents with
congestive heart failure of New York Health Association class
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III or class IV, and patents with unstable coronary syndrome
were explicitly excluded [15].
Can we reconcile these contradictory observations? Clearly,
the model studied by Indrambarya and colleagues markedly
differs from the previous studies: while the latter studies
focused on short-term AVP infusion during vasodilatory shock
with or without a cardiogenic component, the former investi-
gated the effects of AVP over several days after myocardial
ischaemia without overt circulatory shock [1]. In fact, none of
the experimental groups presented with a major drop in mean
blood pressure, and deterioration of behaviour, grooming, or
activity level was not observed at all. Consequently, the
adequacy of the model might be a matter for debate.
Nevertheless, it must be emphasized that the AVP effects
were unrelated to any modification of cardiac loading
parameters and were completely absent in sham-operated
animals. Indrambarya and colleagues therefore elegantly
demonstrate that cardiac ischaemia and subsequent
reperfusion injury may specifically contribute to the
deleterious side effects of AVP. This observation is in good
agreement with previous authors reporting that increased
circulating vasopressin levels predispose to persistent
pronounced myocardial ischaemia [16], most probably as a
result of an attenuated modulatory role of nitric oxide and the
release of vasonconstrictor prostanoids [17].
Interestingly, although cardiac function was nearly identical in
the three experimental groups at day 3 after myocardial
ischaemia, mortality was significantly higher in the AVP-
treated mice. The authors speculate that this observation
mirrors sudden cardiac arrhythmia events, which are referred
to an increased membrane excitability that results from a
vasopressin-related blockade of cardiomyocyte ATP-
dependent potassium (KATP) channels. Clearly, infusing vaso-
pressin has been reported to induce arrhythmia (for example,
torsade de pointes) even without evidence of myocardial
ischaemia [18,19]. In addition, the deleterious consequences
of KATP channel blockade during myocardial ischaemia are
well established [20]. Nevertheless, it remains open whether
KATP channel blockade is the underlying mechanism of a
vasopressin-related cardiac arrhythmia: KATP channel blockers
(for example, glibenclamide) can prevent cardiac arrhythmia
associated with myocardial ischaemia, and compounds
selective for sarcolemmal KATP channels represent a new
class of ischaemia-selective anti-arrhythmic drugs [21].
What can we conclude from the study by Indrambarya and
colleagues? Safety issues on the clinical use of AVP remain a
matter of concern. Given its vasoconstrictor properties, which
are not accompanied by positive inotropic qualities such as in
the case of its comparably potent standard care competitors –
that is, the catecholamines noradrenaline and adrenaline –
AVP may depress cardiac function as a result of impaired
coronary blood flow despite increased coronary artery per-
fusion pressure. Indrambarya and colleagues now show that
cardiac ischaemia may specifically contribute to (or even
enhance?) the deleterious side effects of AVP independently
of its afterload effects. Consequently, the authors caution the
use of AVP in patients with underlying cardiac failure – in
particular, ischaemic heart disease – thus further
emphasizing a previous commentary in this journal: ‘Vaso-
pressin in vasodilatory shock: ensure organ blood flow, but
take care of the heart!’ [22].
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